Drug Interactions between horse chestnut and Ofev
This report displays the potential drug interactions for the following 2 drugs:
- horse chestnut
- Ofev (nintedanib)
Interactions between your drugs
horse chestnut nintedanib
Applies to: horse chestnut and Ofev (nintedanib)
GENERALLY AVOID: When administered systemically, horse chestnut may theoretically potentiate the effects of anticoagulants, platelet inhibitors and other agents that affect hemostasis, possibly increasing the risk of bleeding and bruising. Horse chestnut contains the coumarin glycosides aesculetin, fraxin, and scopolin.
MANAGEMENT: Patients should consult a healthcare provider before taking any herbal or alternative medicine. Until more information is available, consumption of horse chestnut should preferably be avoided during use of anticoagulants, platelet inhibitors, or other agents that can cause bleeding. In patients who have used horse chestnut extensively prior to receiving these agents, the potential for an interaction should be considered. Close clinical and laboratory monitoring for bleeding complications is recommended. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, nosebleeds, prolonged bleeding from cuts, bleeding of gums from brushing, red or brown urine, and red or black stools.
References (3)
- (2001) "Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals
- Heck AM, DeWitt BA, Lukes AL (2000) "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm, 57, 1221-7; quiz 1228-30
- Therapeutic Research Faculty (2008) Natural Medicines Comprehensive Database. http://www.naturaldatabase.com
Drug and food interactions
nintedanib food
Applies to: Ofev (nintedanib)
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of nintedanib. After food intake, nintedanib exposure increased by approximately 20% compared to administration under fasted conditions. Absorption was also delayed, as indicated by an increase in the median time to reach maximum plasma concentration (Tmax) from 2 hours in the fasted state to approximately 4 hours under fed conditions, irrespective of the type of food ingested. In an in vitro study, mixing nintedanib capsules with a small amount of apple sauce or chocolate pudding for up to 15 minutes did not have any impact on their pharmaceutical quality, but swelling and deformation of the capsules were observed with longer exposure time due to water uptake of the gelatin capsule shell. Therefore, administration with soft food would not be expected to alter the clinical effect of nintedanib when taken immediately.
GENERALLY AVOID: Grapefruit and grapefruit juice may increase the plasma concentrations of nintedanib, which has been shown to be a substrate of the P-glycoprotein (P-gp) efflux transporter and a minor substrate of the CYP450 3A4 isoenzyme. The proposed mechanism is inhibition of both P-gp-mediated efflux in the gut wall as well as CYP450 3A4-mediated first-pass metabolism in the intestinal tract by certain compounds present in grapefruit.
MANAGEMENT: Nintedanib should be administered with food to reduce the incidence of gastrointestinal effects. Nintedanib capsules may be taken with water or a small amount (teaspoonful) of cold or room temperature soft food, such as apple sauce or chocolate pudding, and must be swallowed whole (unchewed) immediately, to ensure the capsule stays intact. Food containing grapefruit, grapefruit juice, Seville orange (a citrus relative of the grapefruit), or Seville orange juice should be avoided during treatment with nintedanib.
References (5)
- (2024) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim
- (2024) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim (Canada) Ltd
- (2025) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim Ltd
- (2024) "Product Information. Ofev (nintedanib)." Boehringer Ingelheim Pty Ltd, 2
- (2024) "Product Information. Vargatef (nintedanib)." Boehringer Ingelheim Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.